Viral Genetics Inc. Releases Initial Findings of Lyme Disease Study

SAN MARINO, Calif.--(BUSINESS WIRE)--Viral Genetics, Inc. (OTC:VRAL), a biotechnology company that discovers and develops immune-based therapies, today unveiled to the general public initial findings of its ongoing Lyme Disease study. Viral Genetics initially unveiled its new model and early findings on Saturday, October 18th, at the 2008 International Lyme & Associated Diseases Society (ILADS) Scientific Session. The study, which was financed by a grant specifically allocated for Lyme Disease research, could also potentially offer answers to other immune-based diseases including HIV/AIDS. The team hopes the study will settle the longstanding and controversial debate in the medical community over methods of treatment.

Back to news